RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 116 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $125,542 | +302.0% | 84,826 | +302.0% | 0.00% | – |
Q4 2023 | $31,232 | +37.7% | 21,103 | 0.0% | 0.00% | – |
Q3 2023 | $22,686 | -16.8% | 21,103 | +0.6% | 0.00% | – |
Q2 2023 | $27,264 | -2.3% | 20,972 | 0.0% | 0.00% | – |
Q1 2023 | $27,893 | -89.6% | 20,972 | -73.4% | 0.00% | – |
Q1 2021 | $269,000 | -60.4% | 78,823 | -59.0% | 0.00% | -100.0% |
Q4 2020 | $679,000 | +46.0% | 192,447 | -0.0% | 0.00% | 0.0% |
Q3 2020 | $465,000 | +17.4% | 192,450 | -11.1% | 0.00% | 0.0% |
Q2 2020 | $396,000 | +63.0% | 216,582 | +38.8% | 0.00% | 0.0% |
Q1 2020 | $243,000 | -27.7% | 156,006 | +0.4% | 0.00% | 0.0% |
Q4 2019 | $336,000 | +4.0% | 155,392 | -10.0% | 0.00% | 0.0% |
Q3 2019 | $323,000 | +1142.3% | 172,697 | +1617.5% | 0.00% | – |
Q2 2019 | $26,000 | -10.3% | 10,055 | -9.4% | 0.00% | – |
Q1 2019 | $29,000 | -29.3% | 11,098 | -35.6% | 0.00% | – |
Q4 2016 | $41,000 | – | 17,229 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |